CT-ED/MD calibration curve commissioning and end-to-end validation of HyperSight CBCT-Based dose calculation for online adaptive radiotherapy
In brief
One HyperSight calibration curve kept all 50 phantom dose checks within 2%
Across 10 treatment plans for five disease sites, dose calculations using one 125-kV calibration curve matched phantom measurements within 2% in all 50 point-dose comparisons; target mean doses differed from simulation CT by no more than 0.46%. The results support a simpler commissioning workflow, but validation in phantoms does not establish accuracy in patients.
- Journal
- Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB) (Q2)
- Published
- 15 November 2026
- Study design
- Unclassified
- Evidence level
- Level 5, Expert Opinion (CEBM 5)
- Authors
- Xiangyin Meng, Yaoying Liu, Xiaoshen Wang, Shoubang Luo, Heling Zhu, Zhiqun Wang, et al.
- PMID
- 43035028
- DOI
- 10.1016/j.ejmp.2026.107241
Why clinicians should know about it
- Picked for Medical Physics (top studies of the week, 22 November 2026): End-to-end phantom validation of adaptive CBCT dose calculation
Abstract
PURPOSE: To establish a CT number-to-electron/mass density (CT-ED/MD) calibration curve for the HyperSight cone-beam CT (CBCT) system on the Ethos platform, perform end-to-end dosimetric validation, and evaluate whether a single curve applies across kV imaging energies. METHODS: An electron density phantom (CIRS 062 M) was scanned at 125 and 140 kV and reconstructed using iterative CBCT (iCBCT) Acuros and metal artifact reduction (MAR) algorithms. A 125-kV curve was generated from the averaged Acuros/MAR HU values. Ten intensity-modulated radiotherapy/volumetric-modulated arc therapy plans spanning five disease sites (glioma, brain stereotactic radiation therapy (SRT), mediastinal tumor, lung stereotactic body radiation therapy (SBRT), and prostate cancer) were created on simulation CT for anthropomorphic head, thorax, and pelvis phantoms and recalculated on HyperSight images using the single curve. Validation included ionization-chamber point-dose measurement, 3D gamma analysis, dose-volume histogram comparison, and equivalence testing. RESULTS: The averaged 125-kV curve agreed closely with the Philips 120-kV simulation CT curve. All 50 point-dose comparisons fell within ± 2% (82% within ± 1%), with mean differences of -0.24% to + 0.03% across disease sites, kV energies, and reconstruction algorithms. Mean body gamma pass rates were 99.79% (1%/1 mm) and 99.97% (2%/2 mm); mean target pass rates were 98.04% and 99.79%. Target mean-dose differences versus simulation CT averaged 0.11% (maximum 0.46%), and equivalence was confirmed within ± 2%. CONCLUSIONS: A single, locally generated 125-kV CT-ED/MD curve based on averaged Acuros/MAR HU values enables clinically acceptable HyperSight-based dose calculation, supporting a simplified single-curve commissioning workflow for online adaptive radiotherapy.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.